Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$17.39 USD
+0.42 (2.47%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $17.40 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -307.00 | -267.00 | 52.83 | -122.86 | -84.71 |
Depreciation/Amortization & Depletion | -11.00 | 6.00 | 8.62 | 4.15 | 0.94 |
Net Change from Assets/Liabilities | -71.00 | 623.00 | -375.62 | 208.06 | 0.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 83.00 | 76.00 | 58.00 | 21.83 | 10.18 |
Net Cash From Operating Activities | -306.00 | 438.00 | -256.17 | 111.17 | -73.46 |
Property & Equipment | -24.00 | -6.00 | -26.08 | -3.06 | -1.93 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 218.00 | -404.00 | 22.21 | -431.31 | 61.14 |
Other Investing Activities | 0.00 | -3.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 194.00 | -413.00 | -3.87 | -434.37 | 59.21 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 33.00 | 23.00 | 232.34 | 438.68 | 1.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 10.00 | 5.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 33.00 | 33.00 | 237.34 | 438.68 | 1.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -79.00 | 58.00 | -22.70 | 115.48 | -13.13 |
Cash at Beginning of Period | 209.00 | 151.00 | 173.62 | 58.14 | 71.27 |
Cash at End of Period | 130.00 | 209.00 | 150.92 | 173.62 | 58.14 |
Diluted Net EPS | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 |
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -97.00 | -4.00 | -307.00 | -226.00 | -155.00 |
Depreciation/Amortization & Depletion | -8.00 | -3.00 | -11.00 | -8.00 | -4.00 |
Net Change from Assets/Liabilities | -55.00 | -37.00 | -71.00 | -47.00 | -38.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 64.00 | 42.00 | 83.00 | 63.00 | 42.00 |
Net Cash From Operating Activities | -96.00 | -2.00 | -306.00 | -218.00 | -155.00 |
Property & Equipment | -4.00 | -4.00 | -24.00 | -18.00 | -8.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -102.00 | -165.00 | 218.00 | 184.00 | 163.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -106.00 | -169.00 | 194.00 | 166.00 | 155.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 231.00 | 229.00 | 33.00 | 30.00 | 24.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 231.00 | 229.00 | 33.00 | 30.00 | 24.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 29.00 | 58.00 | -79.00 | -22.00 | 24.00 |
Cash at Beginning of Period | 130.00 | 130.00 | 209.00 | 209.00 | 209.00 |
Cash at End of Period | 159.00 | 188.00 | 130.00 | 187.00 | 233.00 |
Diluted Net EPS | -1.02 | -0.05 | -1.08 | -0.94 | -1.04 |